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Abstract
The most important studies and guidelines in the topics of lipid, blood pressure and kidney published in 2015 were
reviewed. In lipid research, the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) trial
revalidated the concept “lower is better” for low density lipoprotein (LDL)-cholesterol as a target for therapy,
increasing the necessity of treatment the high-risk patients to achieve LDL-C goals. After these results, ezetimibe
might become the preferred additional drug in the combination therapy of lipid disorders because of oral dosage
form and lower acquisition cost. However, for the statin-intolerant patients and those patients requiring essential
reductions in LDL-C to achieve their goals, new therapies, including PCSK9 inhibitors remain promising drugs. In
blood pressure research, American Heart Association (AHA)/American College of Cardiology (ACC) 2015 guidelines
recommended a target for blood pressure below 140/90 mmHg in stable or unstable coronary artery disease
patients and below 150/90 mmHg in patients older than 80 years of age, however the recent results of the Systolic
Blood Pressure Intervention Trial (SPRINT) trial have suggested that there might be significant benefits, taking into
account cardiovascular risk, for hypertensive patients over 50 without diabetes and blood pressure levels <120/80.
In kidney research, reducing the progression of chronic kidney disease and related complications such as anemia,
metabolic acidosis, bone and mineral diseases, acute kidney injury and cardiovascular disease is still a goal for
clinicians.
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Background: Lipids update 2015
The year 2015 was an important year for lipid research.
The researchers were still focused on best strategies for
dyslipidemia management, by using various combina-
tions of statins with other lipid-lowering drugs or testing
new therapies [1]. First, the IMProved Reduction of Out-
comes: Vytorin Efficacy International Trial (IMPROVE-
IT) revalidated the concept that low density lipoprotein
cholesterol (LDL-C) levels are a relevant treatment goal
[2, 3]. Moreover, the IMPROVE-IT trial showed that the
combination with ezetimibe/simvastatin 10 mg/40 mg
let to an absolute 2.0 % reduction (relative risk reduc-
tion: 6.4 %; p = 0.016) of the risk of cardiovascular (CV)
events (a composite of CV death, myocardial infarction
[MI], unstable angina requiring rehospitalization,
coronary revascularization or stroke) in contrast to sim-
vastatin 40 mg alone with 7-year number needed to treat
(NNT) = 50 [2]. IMPROVE-IT trial also demonstrated
that the patients with obtained very low LDL-C levels
<30 mg/dl experienced no discrepancies in adverse
effects (events producing discontinuation of therapy,
muscle-related events, cognitive dysfunction, liver
enzymes elevations, or hemorrhagic stroke) than those
with higher LDL-C levels [2]. Beside IMPROVE-IT trial,
another important trial ODYSSEY LONG-TERM
(NCT01507831) with proprotein convertase subtilisin/
kexin type 9 (PCSK9) inhibitor - alirocumab, supported
the hypothesis ‘even lower is even better’ for LDL-C
levels [4], generating more arguments for lower LDL-C
targets <50 mg/dl (1.3 mmol/l), in contrast with the
current targets <70 mg/dl (1.8 mmol/l) for patients at
the highest risk [5]. The same trial also confirmed that
LDL-C goals below <25 mg/dl and even <15 mg/dl were
not connected with the increase of any adverse events
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[5, 6]. Similar results were obtained in the Open-Label
Study of Long-Term Evaluation Against LDL-C (OSLER)
trial with evolocumab [7]. However, the data concerning
the safety of preserving very low LDL-C levels on long
term are still limited [6].
What next after approval of the PCSK9 inhibitors?
Monoclonal antibodies to PCSK-9 can reduce LDL-C
levels by even more than 60 % in statin users [8–10]. Re-
cently, two first PCSK9 inhibitors (evolocumab -
Repatha, Amgen, and alirocumab – Praluent, Sanofi)
have been approved worldwide by both Food and Drug
Administration (FDA) as well as European Medicine
Agency (EMA) for the treatment of uncontrolled LDL-C
levels in high risk patients [10, 11]. According to FDA
and EMA, PCSK9 inhibitors were approved to treat
adult patients with primary hypercholesterolemia (het-
erozygous familial hypercholesterolemia [HeFH] and
non-familial) or mixed dyslipidemia as an adjunct to
diet: a) in patients unable to reach their LDL-C goals
with a maximally-tolerated statin, as a combination ther-
apy with a statin, with or without other lipid-lowering
therapies; and b) for patients who are statin intolerant,
or for whom a statin is contraindicated, PCSK9 inhibi-




The safety and tolerability of evolocumab was tested in
abovementioned OSLER trial on hypercholesterolaemic
patients [12]. Indeed, evolocumab reduced the levels of
LDL-C by 61 % (p <0.001), what was associated with the
significant reduction of CV events (however the study
was not designed to analyze this effect). The researchers
also noticed that neurocognitive events were more com-
mon in the evolocumab vs standard therapy group (0.9
vs 0.3 %) [13]. The safety and efficacy of alirocumab was
tested in a randomized trial on 2341 statin users (ODYS-
SEY LONG-TERM) with LDL-C levels ~ 70 mg per deci-
liter (1.8 mmol per liter) with high CV risk as compared
with the placebo group [14]. The researchers showed a
significant reduction of LDL-C (−62 % from baseline)
with alirocumab as compared to placebo group (p
<0.001) after 24 weeks of therapy [14]. The patients in
the alirocumab group were also observed to have
increased risk of neurocognitive events (1.2 % vs 0.5 %),
myalgia (5.4 % vs 2.9 %), ophthalmologic events (2.9 %
vs 1.9 %) and higher rates of injection-site reactions
(5.9 % vs 4.2 %), compared to placebo group [14]. Simi-
larly to the results in the OSLER trial, the rate of CV
events was significantly decreased in alirocumab than in
placebo group (1.7 % vs 3.3 %, p = 0.02, however again
the study was not designed to analyze these outcomes)
[14]. The efficacy and safety of alirocumab and
evolocumab on major CVD events at 5 years is still under
evaluation in ODYSSEY OUTCOMES (Evaluation of Car-
diovascular Outcomes after an Acute Coronary Syndrome
during Treatment with Alirocumab; NCT01663402) [15]
and FOURIER (Further Cardiovascular Outcomes
Research with PCSK9 Inhibition in Subjects with Elevated
Risk; NCT01764633) [16] trials. The results will be avail-
able in 2017. The third PCSK9 inhibitor – bococizumab
(Pfizer) has been also under evaluation, and two trials –
the Studies of PCSK9 Inhibition and the Reduction of vas-
cular Events-1 (SPIRE-1) and SPIRE-2 are ongoing, and
the first results will be also available in 2017 (https://clinic
altrials.gov/ct2/show/NCT01975376). The issue of poten-
tially increased risk of neurocognitive disorders is a matter
of further investigations (and their association with very
low levels of LDL-C), especially after publication of recent
meta-analysis, suggesting significant increase of these
PCSK9 possibly related side effects (https://clinicaltrials.
gov/ct2/show/NCT01975389?term=SPIRE-2&rank=1).
There is also specially designed study (ongoing) – the
Evaluating PCSK9 Binding antiBody Influence oN coGni-
tive HeAlth in High cardiovascUlar Risk Subjects (EBBIN-
GHAUS) - to analyze the effect of evolocumab therapy on
the risk of neurocognitive disorders (https://clinicaltrials.
gov/ct2/show/NCT02207634?term=pcsk9+neurocognitive
&rank=1).
In 2015 there have been a number of new studies and
analyses evaluating of PCSK9 inhibitors effect of different
parameters of lipid profile. The effects of alirocumab
150 mg every 2 weeks on lipoprotein a [Lp(a)] levels in hy-
percholesterolemic on lipid-lowering drugs were evaluated
in pooled data from three double-blind, randomized,
placebo-controlled, phase 2 studies (NCT01266876,
NCT01288469, and NCT01288443), after 8–12 weeks of
therapy [17]. This study was an effect of large discussion
on the real effect of PCSK9 inhibitors on Lp(a) – inde-
pendent risk factor of CVD [8, 18, 19]– as the previous
studies suggested that the effect might have been related
to the baseline Lp(a) values [8, 9]. The levels of Lp(a) were
significantly reduced in alirocumab group compared with
placebo (−30.3 % vs −0.3 %, p <0.0001) [17].
The effect of alirocumab 150 mg every 2 weeks on lipo-
protein particle size and concentration in hypercholester-
olemic patients (LDL-C levels ≥100 mg/dL) on a stable
atorvastatin dose was recently tested using nuclear mag-
netic resonance spectroscopy in a phase II, double-blind,
placebo-controlled trial [20]. The mean concentrations of
total very-low-density lipoprotein particle concentrations
(−36.4 % vs +33.4 %), small (−54.0 % vs +17.8 %), large
(−71.3 % vs −21.8 %) and total LDL-P (−63.3 % vs −1.0 %)
subfractions were significantly reduced after alirocumab
therapy vs placebo (all p <0.01). On the contrary, it was
noticed a higher increase of large (+44.6 %) vs medium
(+17.7 %) and small HDL-C particles (+2.8 %) and total
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HDL-C particles (+11.2 % vs +1.4 %, p <0.01). in aliro-
cumab group as compared to placebo group [20]. These
results are very important taking into account the con-
tinuing discussion on the role of different subfractions/
subpopulations on LDL-C and HDL-C (as well so-
called dysfunctional HDL) on the progression of ath-
erosclerosis [21–25].
A Meta-Analysis of 20 Randomized Controlled Trials
(RCTs) (n = 9880 patients) evaluated the efficiency and
safety of PCSK9 inhibitors on hypercholesterolemia [26].
It has been shown that PCSK9 inhibitors significantly
decreased LDL-C, total cholesterol, triglycerides,
apolipoprotein-B and Lp(a) levels and increased HDL-C
and apolipoprotein-A1 levels [26]. No significant differ-
ence in terms of the discontinuation of treatment and
treatment-emergent adverse events between the two
groups was observed [26]. Another meta-analysis of 24
RCTs (n = 10 159 patients) compared the effects of
PCSK9 inhibitors vs placebo on lipid and CV events
[27]. The levels of LDL-C, total cholesterol, and Lp(a)
were significantly reduced (48, 31 and 26.5 %, respect-
ively, all p <0.001), while the level of HLD-C was signifi-
cantly increased (6 %, p <0.001) in PCSK9 inhibitors vs
placebo groups [27]. Despite the fact that the number of
CV events was very small, the authors showed reduced
rate of MI with use of PCSK9 antibodies (odds ratio [OR]
049, 95 % Cl: 0.26 to 0.93; p = 0.030), all-cause mortality
(OR 0.45, 95 % CI: 0.23 to 0.86; p = 0.015), and CV mor-
tality (OR 0.50, 95 % CI: 0.23 to 1.10; p = 0.084 [27].
Consecutively, another meta-analysis of 25 randomized
controlled trials (n = 12 200 patients) tested the safety and
efficacy of alirocumab and evolocumab as compared with
placebo in terms of the discontinuation of treatment
and treatment-emergent adverse events [28]. The risk
of injection-site reactions was increased after alirocu-
mab (RR = 1.48; 95 % CI = 1.05 to 2.09), but not after
evolocumab therapy (RR = 1.06; 95 % CI = 0.67 to 1.67), as
compared with placebo [28]. As compared with control,
alirocumab decreased the rates of death and abnormal
kidney function, whereas evolocumab decreased the rate
of abnormal liver function (RR = 0.43; 95 % CI = 0.20
to 0.93) [28]. Alirocumab also reduced the risk of MI
by 51 % (p = 0.03) and of all-cause mortality by 55 %
(p = 0.015) [28].
A recent retrospective, cross-sectional, observational
study evaluated the clinical characteristics of 164 PCSK9
gain of function (GOF) mutation carriers [29]. It was
noticed that 16 different PCSK9 GOF mutations were
related to various severe LDL-C levels [29]. Than the
PCSK9 GOF mutation carriers were randomized to be
treated during 8 weeks with either alirocumab or pla-
cebo [29]. After 2 weeks of treatment it was noticed a
significant decrease - 62.5 % vs 53.7 % (p <0.0001) of
LDL-C levels and after 8 weeks of treatment the
observed reduction was even 73 % (p <0.0001) of LDL-C
levels in alirocumab vs placebo group [29]. It is very
important study, indicating large effectiveness of PCSK9
inhibitors even in the patients with highest CV risk with
genetic predisposition. Another PCSK9 inhibitor, bococi-
zumab, has been recently tested for safety in experimen-
tal studies on pregnant Sprague-Dawley (SD) rats [30].
The maternal, fetal exposure, tolerability and pharmaco-
dynamic effects and definitive embryo-fetal development
toxicity following maternal administration of bococizu-
mab were evaluated [30]. The results indicated no
embryo-fetal toxicity of bococizumab administration in
pregnant rats, revalidating the rats as proper models for
the safety evaluation [30]. This important study as the
first indicates that PCSK9 inhibitors might be effective
and especially safe as a potential lipid lowering therapy
in pregnant women group, where we have very limited
options to treat dyslipidemia effectively [31–33].
Bococizumab has been also observed to be efficacious
and safe at a dose 150 mg every 2 weeks in a phase II
clinical trial on 354 hypercholesterolemic statin users
(LDL-C ≥80 mg/dL) [34]. After 12 weeks, the most
effective bococizumab doses to decrease LDL-C levels
were the 150 mg every 2 weeks (−53 mg/dl) and the
300 mg dose every 4 weeks (−45 mg/dL) [34]. Further-
more, the safety and efficacy of bococizumab 150 mg
every 2 weeks is currently tested in high risk patients for
cardiovascular events in two placebo-controlled phase
3 trials, SPIRE-1 (n = 17 000 patients with LDL-C
levels =70–100 mg/dl) [35] and SPIRE-2 (n = 9000
patients with LDL-C levels ≥100 mg/dl) [36]. The final
data will be available for SPIRE-1 trial in June 2018
and for SPIRE-2 trial in March 2018.
Statin intolerance – the discussion goes further
The International Lipid Expert Panel (ILEP) recently
recommended a unified definition for statin intolerance
[37, 38] supplementing the EAS statement on statin
associated muscle symptoms (SAMS) [39]. The National
Lipid Association’s Muscle Safety Expert Panel proposed
a myalgia clinical index score [40]. Taking all these into
account, it seems, that definition of statin intolerance -
the inability to tolerate a dose of statin required reducing
a person’s CV risk sufficiently – is the easiest to under-
stand not only by the specialists but especially by general
practitioners. The discussion around statin intolerance/
statin induced myopathy (SIM)/statin associated myop-
athy is mainly connected to the fact that the lipidologists
face the challenge of large discontinuation of statin ther-
apy- even 75 % within 2 years, accusing in about 60 % of
cases statin-associated muscle symptoms [41]. Therefore,
the awareness of different statin therapy-related side
effects might result in effective prevention of this
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unfavorable phenomenon, fast diagnosis and implemen-
tation of suitable management [37, 38].
Besides muscle symptoms in statin intolerant patients,
various statin-side effects such as sleep problems, hair
loss, joint pains, pseudo-lupus syndrome, gastroentero-
logical disorders, peripheral neuropathy, sexual function
problems, weight change, have been described [42–44].
The main problem however is associated to the fact that
we have not had enough data in order to confirm the
causality of statin therapy and the occurrence of these
symptoms. A recent systematic review and meta-analysis
of five trials comprising nine treatment arms showed
that statins did not modified the duration and efficacy of
sleep, entry to stage I, and latency to stage I sleep, but
significantly decreased the number of awakenings and
wake time [45].
Today, the main challenge associated with statin ther-
apy in the context of statin intolerance, after elimin-
ation of various causes of muscle symptoms (as well as
nocebo effect phenomenon), is discontinuation of statin
therapy (or reduction of dose) and then re-administration
(rechallenge) of very low dose of statins and slow consecu-
tive up titration, until the maximally tolerated dose is
established [46]. It is important to emphasize that using
“take your time” approach we are able to keep the statin
therapy in even 90 % of patients previously suggested as
statin intolerant. Taking into account the above definition
it does not mean these patients are not statin intolerant
(=partial intolerance), however, it is important to
emphasize that having and opportunity to use even small
dose of statin, we are able to prevent CV risk much more
effectively [47–49].
Some potential mechanisms of statin-induced myop-
athy have been described, including raised atrogin-1
expression, reduced dolichols or decreased cholesterol
synthesis and production of prenylated proteins [50].
Recently, it has been suggested that statin-induced
myopathy might be related to mitochondrial complex III
inhibition, identifying a new target for therapy [51].
More recent studies showed that the carriers for carni-
tine palmitoyltransferase II deficiency and McArdle dis-
ease have increased prevalence of statin-induced
myopathy [52]. The research of statin intolerance
phenomenon was also concentrated on gene variants
involved in metabolic pathways, such as deficiency of co-
enzyme Q, isoprenoid production or fatty acid oxidation
[53]. Additionally, the variants of genes coding for the
cytochrome P450 (CYP) enzyme superfamily were inten-
sively studied [54]. A recent genome-wide association
study showed that the ‘G’ minor allele of rs13064411 in
the WD repeat domain 52 gene is linked to LDL-C reac-
tion to statins and statin-induced PCSK9 levels [55],
whereas the same minor allele of this single-nucleotide
polymorphism was associated with decreased LDL-C
lowering response to statins [56]. Additionally, the
minor allele of exon 12 of the LDL receptor (LDLR)
gene, situated in the β-propeller region, changes the
LDL-R intracellular distribution in a hepatoma cell line
[57]. Moreover, a comprehensive comparison of LDLR
variants upon ethnicity was recently performed [58]. It
has been revealed that rs1003723, rs5925, rs688,
rs1799898, rs6413504 were more prevalent in Euro-
peans, rs14158 in Asians and rs11669576 in Africans
[58]. Therefore it seems that not only statin intolerance
but also lipid lowering drug response and LDL-C reduc-
tion might be genetically determined.
Different strategies have been tried for the manage-
ment of statin intolerance phenomena. First it needs to
emphasize that there is common agreement that before
therapy implementation of statin intolerance, we should
consider always asking for family history of statin-
related side effects, about physical exertions, as well as
checking the level of thyroid hormones and vitamin D
concentration. Some also consider CoQ10 concentration
measurement [9, 37, 38]. Since statins obstruct the coen-
zyme Q10 (CoQ10) production, therefore the hypothesis
of CoQ10 deficiency involvement in statin-associated
myopathy quickly appeared [59]. A systematic review
and meta-analysis of nine randomized controlled trials
(n = 302 patients) showed no effects of CoQ10 supple-
mentation on statin-induced myopathy, however it needs
to be emphasized that CoQ10 was administered at doses
up to 400 mg/day only [60]. The update of this meta-
analysis with CoQ10 supplementation doses up to
600 mg/day showed, however, the same negative results
[61]. Another factor potentially susceptible for involve-
ment in statin-induced myopathy is the deficiency of
vitamin D levels [62]. Indeed, a systematic review and
meta-analysis of seven randomized controlled trials (n =
2420 patients) showed that low vitamin D levels are
associated with myalgia in statin users [63]. Recent
cross-sectional study on 5907 participants ≥40 years old
proved that statin users with 25(OH)D <15 ng/mL had
1.9 times higher odds of myopathy compared to non-
statin users [64]. Another study examined the relation
between risk of statin-induced myopathy and genetic
polymorphism in the vitamin D receptor (VDR) [65].
The study showed a four times greater risk of myopathy
in individuals homozygous for the C allele in the VDR
polymorphism TaqI (rs731236) (RR 4.37, 95 % CI: 1.9–10.1,
p <0.01) and in patients with 25OHD levels <50 nmol/L
(RR 4.2; 95 % CI: 1.7–10.2; p <0.01) [65].
PCSK9 inhibitors – evolocumab and alirocumab -
seem to be the safe and very effective alternative for the
high risk patients with statin intolerance [66, 67], how-
ever bococizumab is still under development to treat sta-
tin intolerance (NCT Trial Identifier: NCT02135029).
Another option is ezetimibe, especially now, when we
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have strong CV data supporting its efficacy and safety
[6, 68]. The results of IMPROVE-IT trial reconsidered
ezetimibe as a potent LDL-C lowering agent for patients
after acute coronary syndrome, including statin intoler-
ant patients, and revalidated the concept “even lower is
even better” for LDL-C levels [6, 69]. Indeed, the trial
showed that ezetimibe/simvastatin combination led to
an absolute 2.0 % reduction (relative risk reduction:
6.4 %) of the risk of CV events vs simvastatin alone, at
7 years with [69]. The results at only 5.5 years of the
IMPROVE-IT trial showed no significant increase in
new-onset diabetes in patients on ezetimibe/simvastatin
combination vs simvastatin only users [69]. The implica-
tions of IMPROVE-IT trial have been recently evaluated
in a large health care system [70]. The study showed that
69,508 (31.6 %) of the 219,625 patients with acute cor-
onary syndrome, might be ideal candidates for ezetimibe
therapy based on the following criteria: LDL-C = 50–
125 mg/dL and no use of statins more potent than sim-
vastatin 40 mg. However, new LDL-C lowering drugs as
an add-on therapy to statins or in place of statins in
statin-intolerant patients are still under development,
because of the modest efficacy of ezetimibe (about add-
itional 15–20 % LDL-C reduction) [71].
HDL-C remains a target for therapy?
It is already known that the most important mechanism
by which HDL-C exerts its anti-atherogenic effects is
the reverse cholesterol transport (RCT) [72]. Since cho-
lesteryl ester transfer protein (CETP) is a key regulator
of RCT, potential drugs to inhibit CETP for increasing
HDL-C levels quickly appeared [73]. Torcetrapib, the
first CETP inhibitors developed and tested in clinical tri-
als, decreased by 25 % the levels of LDL-C and increased
by 70 % the levels of HDL-C [74]. The development of
Torcetrapib was soon after interrupted after observing
an increase rate of the CV and non-CV mortality (due to
significantly elevated blood pressure [BP] as a result of
increased synthesis of endothelin-1 and aldosterone)
[74]. Anacetrapib and dalcetrapib were the next CETP
inhibitors developed, with a good efficacy and tolerability
in phase I and II clinical trials [75]. Data and Safety
Monitoring Board (DSMB) soon recommended the
interruption of the development of dalcetrapib upon no
clinically efficacy noticed in phase III clinical trials [76].
The efficacy of anacetrapib as LDL-C lowering agent
was evaluated in the Study to Assess the Tolerability and
Efficacy of Anacetrapib Co-administered With Statin in
Participants With Heterozygous Familial Hypercholes-
terolemia (REALIZE) trial (n = 204 patients) - a rando-
mised, double-blind, placebo-controlled, phase 3 study
[77]. At week 52, anacetrapib decreased by 36 % the
levels of LDL-C compared with increased levels LDL-C
by 3.7 % with placebo [77]. The patients on anacetrapib
had a slight increase of CV events compared to placebo
(2 % vs. 0 %, p = 0.1544), but a similar number of adverse
events resulting in discontinuation (6 % vs 5 %) [77].
The effects of anacetrapib 100 mg daily vs placebo on
plasma lipids at 24 weeks was evaluated in the Deter-
mining the Efficacy and Tolerability of CETP INhibition
with AnacEtrapib (DEFINE) trial [78]. The percent de-
creases in Friedewald calculation (Fc)-LDL-C and in-
creases in HDL-C with anacetrapib were similar
subgroups by age, gender, diabetes status, lipid-
modifying regimen, and baseline Fc-LDL-C, HDL-C, or
TG. On the other hand, anacetrapib effects on Fc-LDL-
C (−24 % vs −41 %) and HDL-C (+75 % vs +139 %)
appeared to be less in black vs white patients, respect-
ively [78]. The clinical impact of the lipid-modifying
effects of anacetrapib on CVD outcome (n = 30 624 pa-
tients) will be reported in 2017, when the Randomized
EValuation of the Effects of Anacetrapib through Lipid-
modification (REVEAL) trial will be finished (https://
clinicaltrials.gov/ct2/show/NCT01252953). However, the
long half-life of anacetrapid, with plasma levels still no-
ticeable after 2–4 years after the last dose, might cause
some problems in any attempt for the approval of this
drug. On the other hand, it seems that anacetrapib is the
most potent CETP inhibitor taking into account HDL-C
increase (even +140 %) and reduction of LDL-C (even
−40 %), therefore there is a chance that REVEAL results
might be positive. Evacetrapib, another CETP inhibitor,
was tested in A Study of Evacetrapib in High-Risk Vas-
cular Disease (ACCELERATE) trial (NCT01687998), a
phase 3, multicenter, randomized, double-blind, placebo-
controlled trial (n = 12,092 patients) [79]. The trial was
interrupted in October 2015 since an insufficient efficacy
in obtaining the primary endpoint (the first occurrence
in the composite cardiovascular events of cardiovascular
death, myocardial infarction, stroke, coronary revascular-
ization, or hospitalization for unstable angina) was
noticed. However the safety arm of this study has been
still being continued.
Until now, the therapies that modulate HDL-cholesterol
levels have failed to reduce outcomes, leading to a more in-
tense research of HDL functionality [80–82]. It is well
known that the cholesterol is removed from macrophages
within the arterial walls back into the bloodstream and out
to the liver through the cholesterol-efflux pathway [83, 84].
Therefore, it was assumed that measuring cholesterol-
efflux pathway might be a more reliable marker for CVD,
compared with plasma HDL-C levels [85].
Selected new drugs in the phase of development
RVX-208
RVX-208 (RVX-000222) is a novel BET bromodomain
antagonist and a small-molecule stimulator of apolipo-
protein (Apo)-AI gene expression, developed by
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Resverlogix Corp (USA) for coronary artery disease
(CAD) treatment [86]. Experimental studies reported
that RVX-208 is capable of increasing plasma Apo A-I
levels and pre-beta-HDL particles through RCT [87].
The ApoA1 Synthesis Stimulation and Intravascular
Ultrasound for Coronary Atheroma Regression Evalu-
ation (ASSURE) is a new phase 2b double blind, ran-
domized, multicenter trial (n = 323 patients) that used
intravascular ultrasound (IVUS) technology to evaluate
the effects of RVX-208 vs placebo on atherosclerosis
progression during 26 weeks [88]. The patients on RVX-
208 had increased plasma levels of Apo A-I (12.8 % vs
10.6 %, p =0.18) and HDL-C (11.1 % vs 9.1 %, p =0.24)
and decreased plasma levels of LDL-C (15.8 % vs 17.9 %,
p = 0.55) as compared to placebo [88]. Moreover, RVX-
208 decreased the change in percent atheroma volume
(0.40 % vs 0.30 %, p = 0.81) and total atheroma volume
(4.2 mm3 vs 3.8 mm3, p = 0.86), but abnormally in-
creased liver enzymes (7.1 vs 0 %, p = 0.009). The
other study - The Study of Quantitative Serial Trends
in Lipids with Apolipoprotein A-I Stimulation (SUSTAIN,
NCT01423188) (https://clinicaltrials.gov/ct2/show/NCT
01423188) aimed to assess the lipid efficacy, safety and
tolerability of RVX-208. 176 patients with low levels of
HDL-C were randomized to receive RVX-208 100 mg bid
(n = 88) or placebo (n = 88) for 24 weeks. The primary effi-
cacy parameter was the percentage change in HDL-C
levels that has been met successfully (p <0.0001). Also, the
secondary endpoints, increased apoA-I (p <0.0004), total
and large HDL particles (p <0.004 for both) as well as re-
duced hsCRP levels at 12 weeks (p <0.003) were observed
[87]. Taking into account some opposite results larger
trials are still needed to confirm atheroprotective potential
of novel HDL-targeted therapy with RVX-208, as well as
its safety [87].
ETC-1002
ETC-1002 is another new very potent LDL-C lowering
drug developed by Esperion Therapeutics [89]. This drug
has beneficial effects on proatherogenic lipids through
enhance of the fatty acid oxidation and inhibition of
fatty acid and sterol synthesis in experimental models
[90, 91]. A single-center, double blind, placebo-
controlled trial (n = 60 patients) assessed the efficacy and
safety of ETC-1002 in patients with type 2 diabetes mel-
litus [92]. The levels of both LDL-C (43 ± 2.6 % vs 4 ±
2.5 %, p <0.0001) and high-sensitivity C-reactive protein
were decreased (44 % vs 11 %, p = 0.0011) in ETC-1002
group compared with placebo group at 29 days after
treatment [92]. Another multicenter, randomized, double
blind, placebo-controlled trial (n = 177 patients) showed
the efficacy (significantly decreased by 27 % the levels of
LDL-C across a broad range of baseline triglycerides)
and safety of ETC-1002 compared to placebo [93]. A
new multicenter, double-blind, 8-week trial (n = 56 pa-
tients) evaluated the efficacy and safety of ETC-1002 in
statin intolerant patients [94]. ETC-1002 decreased by
28.7 % the plasma levels of LDL-C more than placebo
(95 % confidence interval, −35.4 to −22.1; p <0.0001)
[94]. Furthermore, it has been shown that ETC-1002 has
a similar safety and tolerability, but a greater capacity of
LDL-C lowering as ezetimibe [95].
Background: Blood pressure update 2015
The American Heart Association/American Society of
Cardiology/American Society of Hypertension 2015
guidelines on treatment of hypertension in patients with
coronary artery disease recommend that the target BP
should be below 140/90 mmHg in patients with stable
coronary artery disease (CAD) and with an acute coron-
ary syndrome (ACS) if they are aged 80 years and youn-
ger and the target BP below 150/90 mmHg if they are
older than 80 years of age [96–99]. Consideration can be
given to lower the BP to below 130/80 mmHg with a
class IIb C indication [96–99]. Octogenarians should be
checked for orthostatic changes with standing and a sys-
tolic blood pressure (SBP) below 130 mmHg and a dia-
stolic blood pressure (DBP) below 65 mmHg should be
avoided [96–99]. Caution is advised in reducing DBP
below 60 mmHg in patients with diabetes mellitus (DM)
or in patients older than 60 years of age [96–99].
Antihypertensive therapy
Coronary artery disease
Coronary risk factors should be treated including cessa-
tion of smoking and treatment of hypertension, dyslipid-
emia, DM, obesity, and physical inactivity [96–99].
Dietary sodium should be reduced [100, 101].
Beta-blockers are the initial antihypertensive drugs to
use in CAD patients who have angina pectoris, who have
had a myocardial infarction (MI), and in those who have
left ventricular systolic dysfunction unless contraindi-
cated [96–99, 102, 103]. Patients with prior MI and
hypertension should be treated with beta-blockers and
angiotensin-converting enzyme (ACE) inhibitors [96–99,
102–104]. If a third drug is needed, aldosterone antago-
nists may be administered [96–99, 105]. Patients treated
with aldosterone antagonists should not have significant
renal dysfunction or hyperkalemia.
In addition to the beta blockers carvedilol, metopro-
lol CR/XL, and bisoprolol, [96–99, 106] patients with
hypertension, coronary artery disease, and congestive
heart failure should be treated with diuretics and
ACE inhibitors or angiotensin receptor blockers
(ARBs [96–99, 106], and patients with persistent
severe symptoms with aldosterone antagonists [96–99,
105–107]. Hydralazine plus isosorbide dinitrate should
be added to African-American patients with New
Banach et al. Lipids in Health and Disease  (2015) 14:167 Page 6 of 18
York Heart Association class III or IV heart failure
with a reduced left ventricular ejection fraction
(HFrEF) already receiving diuretics, beta blockers, and
an ACE inhibitor or ARB [96–99, 106, 108, 109].
Drugs to avoid in patients with hypertension and
HFrEF include verapamil, diltiazem, doxazosin, cloni-
dine, moxonidine, hydralazine without a nitrate, and
nonsteroidal anti-inflammatory drugs [96–99].
In patients with hypertension, CAD, and heart failure
with a preserved left ventricular ejection fraction
(HFpEF), class I therapeutic indications include control
of systolic and diastolic hypertension, control of the ven-
tricular rate in patients with atrial fibrillation, and treat-
ment of pulmonary congestion and peripheral edema
with diuretics [96–99, 106]. Class IIb therapeutic indica-
tions include use of beta-blockers, ACE inhibitors or
ARBs, or calcium channel blockers (CCBs) [96–99, 106].
Stable angina pectoris
Patients with hypertension and chronic stable angina
pectoris should be treated with beta-blockers plus
nitrates as antianginal agents [96–99]. Hypertension in
these patients should be treated with beta-blockers plus
an ACE inhibitor or ARB with addition of a thiazide or
thiazide-like diuretic if needed. If either the angina
pectoris or the hypertension remains uncontrolled, a
long-acting dihydropyridine CCB can be added to the
therapeutic regimen. Nondihydropyridine calcium channel
blockers such as verapamil and diltiazem cannot be used
if there is left ventricular systolic dysfunction. Combining
a beta-blocker with either verapamil or diltiazem must be
used cautiously because of the increased risk of bradyar-
rhythmias and heart failure developing [96–99].
Acute coronary syndromes
In patients with an ACS, initial management of hyper-
tension should include a short-acting beta1 selective
beta-blocker without intrinsic sympathomimetic activity
such as metoprolol tartrate or bisoprolol [96–99]. Treat-
ment with beta-blockers should be started initially
within 24 h of symptoms. In patients with severe hyper-
tension or ongoing ischemia, intravenous esmolol may
be used [96–99]. In hemodynamically unstable patients
or those with decompensated heart failure, administra-
tion of beta-blockers should be delayed until the patient
is stabilized [96–99].
In patients with an ACS with hypertension, nitrates
can be used to reduce blood pressure or to reduce on-
going myocardial ischemia or pulmonary congestion
[96–99]. However, nitrates should not be administered
to patients with suspected right ventricular infarction or
in those with hemodynamic instability. Intravenous or
sublingual nitroglycerin is preferred initially [96–99].
An ACE inhibitor or ARB should be given to patients
with an ACS [110], especially in patients with an anter-
ior myocardial infarction if hypertension persists, if there
is an decreased left ventricular ejection fraction (LVEF),
or if diabetes mellitus is present [96–99, 111]. If hyper-
tension persists after use of a beta-blocker plus an ACE
inhibitor or ARB, a long-acting dihydropyridine CCB
may be added to the therapeutic regimen [96–99].
Aldosterone antagonists are indicated in patients receiv-
ing beta-blockers plus ACE inhibitors or ARBs after
myocardial infarction who have left ventricular systolic
dysfunction and either heart failure or diabetes mellitus
[96–99]. However, aldosterone antagonists should not be
given if the serum potassium is ≥5.0 mEq/L or if the
serum creatinine is ≥2.5 mg/dL in men or ≥2.0 mg/dL in
women [96–99]. Loop diuretics are preferred to thiazide
and thiazide-type diuretics in patients with heart failure
or in patients with chronic kidney disease and an esti-
mated glomerular filtration rate less than 30 mL/min
[96–99].
Sprint
The American College of Cardiology/American Heart
Association 2016 guidelines for the management of
patients with hypertension will be strongly influenced by
the results from the Systolic Blood Pressure Intervention
Trial (SPRINT) [112]. SPRINT randomized 9,361
patients with a SBP of 130–180 mm Hg and an
increased cardiovascular risk, but without diabetes melli-
tus, history of stroke, symptomatic heart failure within
the past 6 months, a LVEF <35 %, and an estimated
glomerular filtration rate <20 ml/min/1.73 m2 to a SBP
target of <120 mm Hg or to a SBP target of <140 mm
Hg [112]. The patients were aged 50 years and older
with a mean age of 67.9 years. Of the 9,361 patients,
2,636 (28.2 %) were aged 75 years and older, 3332
(35.6 %) were women, 5,399 (57.7 %) were non-Hispanic
white, 2,947 (31.5 %) were black, and 984 (10.6 %) were
Hispanic. Cardiovascular disease was present in 1,877
patients (20.1 %), and the Framingham 10-year cardio-
vascular disease risk score was ≥15 % in 5, 737 patients
(61.3 %).
Blood pressure was measured by use of an automated
measurement system (Model 907, Omron Healthcare).
At 1 year, the mean SBP was 121.4 mm Hg in the inten-
sive treatment group (mean number of antihypertensive
drugs was 2.8) and 136.2 mm Hg in the standard treat-
ment group (mean number of antihypertensive drugs
was 1.8). The intervention was stopped early after a me-
dian follow-up of 3.26 years.
The primary composite outcome was MI, other ACS,
stroke, heart failure, or death from cardiovascular causes
and was reduced 25 % (95 % CI, 11 % to 36 %; p <0.001)
by intensive blood pressure treatment [112]. All-cause
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mortality was reduced 27 % (95 % CI, 10 % to 40 %; p =
0.003) by intensive BP treatment. Heart failure was
reduced 38 % (95 % CI, 16 % to 55 %; p = 0.002)) by
intensive blood pressure treatment. Death from cardio-
vascular causes was reduced 43 % (95 % CI, 15 % to
62 %; p = 0.005) by intensive blood pressure treatment.
The primary composite outcome or death was reduced
22 % (95 % CI, 10 % to 33 %; p <0.001) by intensive BP
treatment. Intensive BP treatment insignificantly
reduced MI by 17 %, caused the same incidence of other
ACS, and insignificantly reduced stroke by 11 %. The
composite renal outcome in patients with chronic kidney
disease (CKD) at baseline was insignificantly reduced
11 % by intensive blood pressure [112].
Intensive BP treatment insignificantly reduced the pri-
mary outcome 18 % in patients with prior CKD and sig-
nificantly reduced the primary outcome 30 % in patients
without prior CKD [112]. Intensive BP treatment signifi-
cantly reduced the primary outcome 33 % in patients
aged 75 years and older and significantly reduced the
primary outcome 20 % in patients aged 50–74 years. In-
tensive BP treatment insignificantly reduced the primary
outcome 16 % in women and significantly reduced the
primary outcome 28 % in men. Intensive BP treatment
insignificantly reduced the primary outcome 23 % in
blacks and significantly reduced the primary outcome
26 % in nonblacks. Intensive BP treatment insignificantly
reduced the primary outcome 17 % in patients with
prior CAD and significantly reduced the primary out-
come 29 % in patients without prior CAD. Intensive BP
treatment insignificantly reduced the primary outcome
17 % in patients with a SBP ≥145 mm Hg, insignificantly
reduced the primary outcome 23 % in patients with a
SBP of 133–144 mm Hg, and significantly reduced the
primary outcome 30 % in patients with a SBP of
≤132 mm Hg [112].
Serious adverse events were similar in both treatment
groups [112]. However, intensive BP treatment caused
more hypotension (2.4 % versus 1.4 %, p =0.001), more
syncope (2.3 % versus 1.7 %, p = 0.05), more electrolyte
abnormality (3.1 % versus 2.3 %, p = 0.02), and more
acute kidney injury or acute renal failure (4.1 % versus
2.5 %, p <0.001). The incidence of bradycardia, injurious
falls, and orthostatic hypotension with dizziness was
similar in both treatment groups [112].
The effects of intensive BP treatment on renal func-
tion, dementia, and cognitive function cannot be inter-
preted until analysis of these end points has been
completed. Data on the association between DBP and
clinical outcomes and serious adverse events also need
to be reported. What are the data if the DBP is reduced
below 70 mm Hg, below 65 mm Hg, and below 60 mm
Hg? Since hypertension is a powerful risk factor for
development of heart failure, especially HFpEF, what
percent of the patients who developed heart failure in
SPRINT developed HFpEF?
The American College of Cardiology/American Heart
Association 2016 guidelines will have to answer on the
basis of expert medical opinion many questions not
answered by SPRINT. What should be the target blood
pressure in diabetics? In The ACTION to Control Car-
diovascular Risk in Diabetes Blood Pressure (ACCORD
BP) trial, reducing the SBP to <120 mm Hg in 4,733
patients insignificantly reduced the composite primary
outcome of myocardial infarction, stroke, or cardiovas-
cular death 12 % but significantly reduced the incidence
of stroke (a prespecified secondary outcome) 41 %, p =
0.01 [113]. The sample size was much larger in SPRINT
than in ACCORD BP, and there were methodological
differences between both trials [114]. A post-hoc analysis
of the results from ACCORD showed that the primary
cardiovascular disease outcome was 26 % lower in
patients randomized to intensive blood pressure treat-
ment and standard glycemia goals than in patients ran-
domized to standard blood pressure treatment and
standard glycemia goals [114, 115].
What should the target blood pressure be in patients
with prior stroke or transient ischemic attack, in patients
younger than 50 years, in patients with HFrEF, and in
patients with HFpEF? Although patients in SPRINT
treated with intensive blood pressure control had a 38 %
significant reduction in development of heart failure,
SPRINT excluded patients with recent heart failure and
patients with a LVEF less than 35 %. In a propensity
score analysis of 7,785 patients with mild to moderate
HFrEF and HFpEF, at 5-year follow-up, a baseline SBP
≤120 mm Hg was associated with increased cardiovascu-
lar and heart failure mortalities and all-cause, cardiovas-
cular, and heart failure hospitalizations that was
independent of other baseline characteristics [116].
SPRINT did not enroll patients living in nursing homes
or in assisted-living facilities? How should we treat frail
elderly patients with hypertension? Data from 1,130 frail
patients, mean age 88 years, living in a nursing home
being treated for hypertension with two or more antihy-
pertensive drugs showed that the SBP should not be
reduced to less than 130 mm Hg [117, 118].
How should SPRINT affect the recommendations
regarding office versus out of office blood pressure mea-
surements? Should SPRINT change the definitions of nor-
mal blood pressure, prehypertension, and hypertension?
What should the threshold and goals be for untreated SBP
between 120 and 140 mm Hg? Finally, because of a higher
incidence of hypotension, syncope, electrolyte abnormal-
ities, and acute kidney injury or failure in patients treated
to a SBP less than 120 mm Hg, these patients will require
more intensive monitoring for serious adverse events with
an increased cost of care [119–122].
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Background: Kidney updates 2015
Glomerulopathies
New conclusive data regarding rituximab administration
in idiopathic membranous nephropathy were reported
[123]. 80 patients with idiopathic membranous nephrop-
athy and persistent nephrotic syndrome treated with
non-immunosuppressive antiproteinuric therapy for
6 months were randomized (1:1) to be treated with ri-
tuximab (375 mg/m2 day 1 and day 8) or with placebo
[123]. The primary composite end point was a reduction
in proteinuria of at least 50 % and an increase in serum
albumin of at least 30 % [123]. Secondary end points
were proteinuria, serum albumin, serum creatinine, and
antibodies against the M-type phospholipase A2 recep-
tor (PLA2R-Ab). There was a significant reduction in
proteinuria but without significant differences between
the two groups at 3 and 6 months. However, the serum
albumin levels increased significantly in the rituximab
group at 3 and 6 months compared with placebo [123].
Additionally, PLA2R antibody levels dropped dramatic-
ally by month 3 in the rituximab group and stabilized
after that. The differences between the two groups were
significant both at month 3 (p <0.001) and at month 6
(p <0.001). Patients were followed for up to 24 months
after the discontinuation of the study regimens. During
this period, rates of remission were significantly higher
in the rituximab group compared to the control group
(64.9 % vs 37.5 %; p = 0.02) and more patients in the ri-
tuximab group achieved a complete response (7 vs 1)
[123].
Diabetic nephropathy
Around 20–30 % of patients with diabetes develop evi-
dence of nephropathy - now the leading cause of end-
stage renal disease (ESRD) and dialysis in the U.S. and in
Europe [124]. The classical risk factors for CKD pro-
gression in diabetic nephropathy are hyperglycemia,
hypertension and dyslipidemia [125]; their rigorous man-
agement could decrease the risk for renal or cardiac
complications. Recently, another risk factor has been de-
scribed: urinary potassium excretion. In an observational
study involving 623 Japanese type 2 diabetic patients
with eGFR ≥60 ml/min/1.73 m2 and a follow-up period
of 11 year, a higher urinary potassium excretion was
associated with a slower decline of renal function and
lower incidence of cardiovascular complications (myo-
cardial infarction, angina pectoris, stroke, and peripheral
vascular disease) [126]. Several possible mechanisms are
incriminated by the authors: 1) a BP lowering effect of K
intake - the higher quartile subgroups showed lower sys-
tolic BP than the lower quartile subgroup; 2) higher
amounts of potassium-rich food items, such as fresh
vegetables and fruits, recognized for their antioxidant
and anti-inflammatory effects; 3) a high potassium
intake is reported to increase endothelium-dependent
nitric oxide production and decrease salt-induced TGF-
β production; these favorable effects may support vascu-
lar protection against atherosclerosis, which might result
in preventing renal and cardiovascular complications.
Recent guidelines regarding the management of
patients with diabetes and advances CKD (stage 3b or
higher) were recently published by ERBP (European
Renal best Practice) [127]. The most important recom-
mendations of this guideline are listed below:
1. Regarding glycemic control
▪ Glycated hemoglobin (HbA1C) remains the
routine reference to assess longer term glycaemic
control in patients with CKD stage 3b or higher;
▪ The authors recommend against tighter
glycaemic control if this results in severe
hypoglycemic episodes (1B);
▪ The authors recommend vigilant attempts
to tighten glycaemic control with the intention
to lower HbA1C when values are >8.5 %
(69 mmol/mol) (1C).
▪ The authors recommend intense self-monitoring
only to avoid hypoglycemia in patients at high risk
for hypoglycemia (2D).
▪ Metformin is still the best choice when choosing
the oral hypoglycemic drugs; the authors
recommend Metformin in a dose adapted to renal
function as a first line agent when lifestyle
measures alone are insufficient to get HbA1C in
the desired range 4 (1B).
▪ The authors also strongly recommend
instructing patients to temporarily withdraw
Metformin in conditions of pending dehydration,
when undergoing contrast media investigations, or
in situations with an increased risk for AKI (1C).
2. Regarding the management of cardiovascular risk in
patients with diabetes and CKD stage 3b or higher
▪ The authors e recommend not omitting
coronary angiography with the sole intention of
avoiding potential contrast-related deterioration of
kidney function in patients with diabetes and CKD
stage 3b or higher (eGFR <45 mL/min) in whom a
coronary angiography is indicated (1D).
▪ Additionally, they recommend that optimal
medical treatment should be considered as
preferred treatment in patients with diabetes and
CKD stage 3b–5 who have stable CAD, unless
there are large areas of ischemia or significant left
main or proximal LAD lesions (1C); moreover,
when a decision is taken to consider
revascularization, CABG is preferred over PCI
in patients with multivessel or complex
(SYNTAX score >22) CAD (1C).
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▪ Additionally, the authors recommend that
patients with diabetes and eGFR <45 mL/min who
present with an acute coronary event should be
treated no differently than patients with CKD and
eGFR <45 mL/min without diabetes or patients
with diabetes without CKD (1D).
3. Regarding cardiovascular protection, the authors:
▪ Recommend that adults with CKD stage 3b or
higher (eGFRmin <45 ml/1.73 m2 or on dialysis)
and diabetes who have a cardiovascular indication
(heart failure, ischaemic heart disease) be treated
with an ACE-I at maximally tolerated dose (1B).
▪ Suggest there is insufficient evidence to justify
the start of an ARB in adults with CKD stage 3b
or higher (eGFRmin <45 ml/1.73 m2 or on
dialysis) eGFR and diabetes who have a
cardiovascular indication (heart failure, ischaemic
heart disease) but intolerance for ACE-I (2B).
▪ Recommend not combining different classes of
renin angiotensin-blocking agents (ACE-I, ARBs
or direct renin inhibitors) (1A).
▪ Suggest starting a selective beta-blocking agent
as primary prevention for sudden cardiac death in
patients with DM and CKD stage 3b or higher and
then continuing it when tolerated (2C). They sug-
gest prescribing lipophilic rather than hydrophilic
beta-blocking agents in patients with diabetes and
CKD stage 3b or higher.
▪ Recommend starting a statin in patients with
DM and CKD stage 3b and 4 (1B).
▪ Suggest a statin be considered in patients with
DM and CKD stage 5 (2C).
▪ Recommend against starting a statin in patients
with DM and CKD stage 5D (1A).
▪ There was no consensus in the guideline
development group on whether or not statins
should be stopped in patients with diabetes with
CKD stage 5D.
4. Regarding BP targets, the authors only suggest:
▪ Against applying lower blood pressure
targets in patients with diabetes and CKD stage 3b
or higher than in the general population (2C).
▪ That in patients with diabetes and CKD stage 3b
or higher but without proteinuria, all blood
pressure lowering drugs can be used equally to
lower blood pressure (2C).
Acute kidney injury
Over the past two decades, major increases in the inci-
dence of acute kidney injury (AKI) have been reported
[128]; even a minor acute reduction in kidney function
is associated with an unfavorable prognosis [129]. Early
AKI detection, optimal patient risk stratification and
adequate treatment may improve outcomes [130, 131].
Several biomarkers have been extensively explored in
the last years, but their ability to detect and predict AKI
progression was inconsistent [132–134]. Two years ago,
Chawla et al. described the furosemide stress test (FST):
in clinically euvolemic patients with early AKI a high
dose furosemide was administrated (1 mg/kg of fur-
osemide in naive patients or 1.5 mg/kg in those with
prior exposure) and urinary output was monitored two
hours after furosemide administration [135]. The ideal
cut-off for predicting progressive AKI during these first
2 h was a urine volume <200 ml (100 ml/h) with a sensi-
tivity of 87.1 % and a specificity of 84.1 % [135]. The
same author, in a recently published study, compared
the performance of several biomarkers for AKI (includ-
ing the fractional excretion of sodium, urine and plasma
NGAL, urine albumin-to-creatinine ratio, urinary IL-18,
kidney injury molecule-1 (KIM-1), TIMP2, IGFBP-7, and
uromodulin), with that of FST for the prediction of sev-
eral clinical end points, including progressive AKI, need
for RRT (renal replacement therapy), and inpatient mor-
tality in the same previous published cohort of 77
patients [136]. FST was the best-tested parameter in pre-
dicting progression of AKI to stage 3, with an area under
the curve (AUC) of 0.87 ± 0.09 (p <0.0001). Additionally,
FST urine output was the only biomarker to significantly
predict RRT (0.86 ± 0.08; p = 0.001). Finally, combining
FST urine output with individual biomarkers using logis-
tic regression did not significantly improve risk stratifi-
cation (ΔAUC, P >0.10 for all). Plasma NGAL, which
performed the best of all the novel biomarkers, had an
AUC of 0.86 when pooled with the FST. In this context,
it seems that FST is the best available diagnostic tool in
predicting the severity of AKI and the need for RRT
[136].
In the last year, several renal protective strategies have
been attempted [137], unfortunately with poor results
[138]. In a large study including 820 patients receiving
elective cardiac surgery, there were no favorable effects
of statin administration on AKI incidence. Following
cardiac surgery and cardiopulmonary bypass renal
ischemia-reperfusion injury, impaired vasodilatation,
neurohormonal activation, oxidative stress, inflamma-
tion, and atheroembolism may promote AKI [139]. Sta-
tins administration might reduce oxidative stress,
improve endothelial function and decrease inflammation
[140, 141]. Moreover, in experimental models of ischemia-
reperfusion, short-term statin treatment decreases renal
dysfunction and inflammation [142, 143]. Based on these
data, the authors administrated high dose atorvastatin a
day before surgery and continued until hospital discharge
in statin naive patients; in those using statins prior to the
study, treatment was administered until the day after sur-
gery (https://www.asn-online.org/education/kidneyweek/
2015/KW15_Late-Breakers.pdf ). There was no difference
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in the rate of AKI between atorvastatin users and placebo
(20.8 % vs 19.5 %; p = 0.75). In fact, in statin treatment-
naïve patients with previous CKD, the rates of AKI were
52.9 % vs 15.8 % for treatment versus placebo, respectively
(n = 36; p = .03). In this context, the study was stopped on
the recommendation of the U.S. Data and Safety Monitor-
ing Board.
Equally, steroid administration failed to reduce AKI
incidence in patients undergoing cardiopulmonary by-
pass surgery. It is well known that cardiopulmonary
bypass determines a systemic inflammatory response
syndrome, which activates several inflammatory cyto-
kines, increases endothelial permeability and postoper-
ative mortality and morbidity [144]. Steroids could
suppress this important inflammatory process. 7826
patients from 80 hospital or cardiac surgery centers
in 18 countries undergoing cardiac surgery with the
use of cardiopulmonary bypass were randomized to
receive either methylprednisolone (250 mg at anesthetic
induction and 250 mg at initiation of cardiopulmonary
bypass) or placebo. Methylprednisolone, compared
with placebo, did not reduce the risk of death at
30 days (154 [4 %] vs 177 [5 %] patients; relative risk
(RR) 0.87, 95 % CI 0·70–1·07, p = 0.19) or the risk of
death or major morbidity (909 [24 %] vs 885 [24 %];
RR 1·03, 95 % CI 0·95–1·11, p = 0.52). Additionally,
the risk of AKI was similar in both groups: (at 14 days: >
50 % increase in creatinine was: 40.9 % in steroid group
versus 39.5 % in placebo; at 30 days –acute dialysis 2.6 %
in metilprednisolone group versus 2.4 % in placebo).
Moreover, because of the adverse-effect profile of the dose
of steroids used in this trial, the investigators make the
grade 1 recommendation that steroids should not be used
in this setting [145].
In patients with mild deterioration of renal function
undergoing cardiac catheterization, it is unclear if hold-
ing ACEI or ARB reduces contrast-induced AKI. In this
circumstances, 208 patients were randomize to hold or
to continue ACEI or ARB prior to coronary angiography;
the primary outcome was the incidence of AKI defined
as an absolute rise in serum creatinine of ≥0.5 mg/dL
from baseline and/or a relative rise in serum creatinine
of ≥25 % compared with baseline measured at 48–96 h
postcardiac catheterization [146]. There was no differ-
ence in the primary outcomes between the groups. How-
ever, there was a lower rise in mean serum creatinine
after the procedure in patients who held ACEI/ARB (0.3
± 0.5 vs 0.1 ± 0.3 mg/dL, p = .03). Moreover, the clinical
composite of death, myocardial infarction, ischemic
stroke, congestive heart failure, rehospitalization for car-
diovascular cause, or need for dialysis pre-procedure oc-
curred in 3.9 % who continued ACEI/ARB compared
with 0 % who held the ACEI/ARB (HR 0.11, 95 % CI
0.01–2.96, p = 0.06) [146].
Electrolyte disturbance
At the end of the last year, two new products were used
to correct hyperkaliemia in renal cohort and general
population. Sodium zirconium cyclosilicate (ZS-9), un-
like traditional organic polymers such as Kayexalate and
the investigational agent patiromer, was engineered with
a highly selective, high-capacity inorganic crystalline lat-
tice structure that preferentially entraps monovalent cat-
ions (specifically K+ and ammonium (NH4+)) over
divalent cations (e.g., Ca2+ and Mg2+) in the gastro-
intestinal tract. Recent favorable data are provided from
the HARMONIZE, a phase 3, multicenter, randomized,
double-blind, placebo-controlled trial. More than half of
all patients studied had stage 3 chronic kidney disease
(estimated glomerular filtration rate <61 mL/min/
1.73 m2) or diabetes, and nearly 60 % or more were on
at least one renin-angiotensin-aldosterone–modifying
medication. Finally, all patients had to be asymptomatic
(without an identifiable cardiac arrhythmia) in order to
be included in the study. The patients (n = 258) received
10 g of zirconium cyclosilicate three times daily in the
initial 48-hour open-label phase had a significant decline
in serum potassium level; median time to normalization
was 2.2 h, with 84 % of patients (95 % CI, 79–88 %)
achieving normokalemia by 24 h and 98 % (95 % CI, 96–
99 %) by 48 h. In the next randomized phase, the largest
dose of ZS-9 (15 g/day for 28 consecutive days) resulted
in the lowest plasma potassium levels (from 5.55 to
4.4 mEq/L). In this short-term study, adverse events
were comparable between zirconium cyclosilicate and
placebo [147].
Cardiovascular diseases in CKD
Left ventricular hypertrophy (LVH) is highly prevalent in
CKD patients [148]. In an observational study including
2410 patients form the Coronary Artery Risk Develop-
ment in Young Adults (CARDIA) cohort, left ventricular
mass index was higher in patients with lower eGFRcys
even after adjusting for potential confounders [149].
Compared with eGFRcys >90 mL/min/1.73 m2 (n =
2,228), eGFRcys of 60 to 75 mL/min/1.73 m2 (n = 29)
was associated with 5.63 (95 % CI, 0.90–10.36) g/m2.7
greater LVMI (p = 0.02). Moreover, every 1 % decline in
eGFR was associated with a 0.40 g/m2.7 increase in
LVMI after 10 years, but without reaching statistical sig-
nificance [149]. Additionally, in patients with rapid
decline in eGFR (379 patients) a statistically higher
LVMI was noted (β coefficient, 1.48; 95 % CI, 0.11–2.83;
p = 0.03) compared with participants without a rapid
eGFRcys decline after adjustment for confounders. The
potential mechanisms for this remain speculative and
may include alterations in the renin-angiotensin-
aldosterone system or vitamin D-PTH-fibroblast growth
factor 23 axis (http://ajkdblog.org/2015/09/24).
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Hypertension
Hypertension is the leading risk factor for death and
disability-adjusted life-years lost during 2010 (http://
www.who.int/healthinfo/global_burden_disease/Global
HealthRisks_report_full.pdf ). Additionally, inter-arm dif-
ferences of BP are associated with increased cardiovascular
and all-cause mortality [150]; this association was showed
in several cohorts, with hypertension, diabetes or estab-
lished cerebrovascular disease but also in general popula-
tion [151, 152]. Similar data was confirmed also in CKD
cohort. In a prospective cohort study of patients with
CKD, the increased interarm systolic blood pressure differ-
ence ≥10 mmHg was found to be an independent predictor
of CV events after a follow-up period of 19 ± 5 months
(HR, 1.802, 95 % CI (1.054–3.079); p = 0.031) [153]. This
association remained significant even after adjustment for
classic risk factors, such as history of CV disease [153].
Anemia
The main reasons for anemia in CKD are reduced
erythropoietin production and iron deficiency [122]. It is
well demonstrated that erythropoietin administration is
associated with hyper viscosity and thrombogenity, and
consequently with increased CV and all-cause morbidity
and mortality [154]. Iron administration, as an addition to
erythropoietin therapy has developed into usual treatment
for renal anemia. On the other hand, there are concerning
data regarding the safety of this therapy; almost half of the
RCT of oral or iv iron therapy reported adverse effects, in-
creased oxidative stress, endothelial damage or kidney
injury [155, 156]. Recent risk/benefit analysis of iron sup-
plementation in patients with CKD not on dialysis was
finished. Thirty one thousand nine hundred seventy-one
adult patients from Taiwan National Health Insurance Re-
search Database with serum creatinine >6 mg/dL and a
haematocrit <28 %, treated already with ESA, were further
divided into two groups with or without iron supplemen-
tation within 90 days after starting ESA therapy [157].
Despite poor enteric absorption and uncertain efficacy for
erythropoiesis by oral iron supplementation, only 17.2 %
of iron users were treated via IV route administration; the
greater part of the patients were treated with oral iron.
This large-scale cohort study showed for the first time that
oral iron as well as lower dose IV iron (<200 mg/month)
supplementation were associated with significant reduced
risk of death among predialysis CKD patients (HR 0.85;
95 % CI 0.80–0.90). Additionally, a lower risk of hospitali-
zations (HR, 0.97; 95 % CI, 0.94–0.99) was founded [157].
This benefit was not showed in patients who were treated
with monthly IV iron >200 m. In contrast, a higher risk of
faster progression to end-stage renal disease (HR, 1.05;
95 % CI, 1.01–1.08) was described. This association is still
a subject of debate. The authors explained that iron sup-
plementation decreased the competing risk of death; the
survivors had more exposure time to pre-ESRD milieu
and an increased risk for progression to ESRD and initi-
ation of renal replacement therapy. Additionally, it was
already showed that higher transferrin saturation (TSAT)
is associated with faster CKD progression in non-dialysis
CKD [158]. Moreover, parenteral iron induces lipid perox-
idation and cell injury in isolated mouse and human tubu-
lar epithelial cells [159] and three observational studies
showed that short-term IV iron administration caused
transient proteinuria and urinary excretion of tubular
enzymes [156, 160, 161].
Most frequently, intravenous iron is recommended for
CKD patients, due to poor absorption of oral iron in this
category of patients. In hemodialysis population there
are several studies showing the benefit of intravenous
iron for replenishing iron stores, improving anemia, and
reducing ESA dosage requirements compared with oral
administration [162]. Different data are recently pub-
lished for CKD patients. Agarwal et al. randomized 136
patients with anemia and iron deficiency and CKD not
on dialysis to either oral ferrous sulfate (69 patients to
325 mg three times daily for 8 weeks) or intravenous
iron sucrose (67 patients to 200 mg every 2 weeks, total
1 g). The primary outcome was the between-group dif-
ference in slope of measured glomerular filtration rate
(mGFR) change over 2 years. The study was stopped
earlier because a higher risk of serious cardiovascular
events and hospitalization for infection was noted in the
group with iron intravenous. There were 36 serious car-
diovascular events among 19 participants assigned to the
oral iron treatment group and 55 events among 17 par-
ticipants of the intravenous iron group (adjusted inci-
dence rate ratio 2.51 (1.56–4.04)). Infections resulting in
hospitalizations had a significant adjusted incidence rate
ratio of 2.12 (1.24–3.64). There was a twofold increase
in hospitalizations for heart failure, about a fourfold in-
crease in hospitalizations for pneumonia, and a more
than threefold increase in risk for skin infections requir-
ing antibiotics in the IV vs the oral iron group. And, al-
though not quite statistically significant, there was a
more than 1.22-fold increase for sepsis (p = .056) in the IV
iron group. The mGFR slope was almost the same in both
groups (oral −3.6 ml/min per 1.73 m2, intravenous −4.0 ml/
min per 1.73 m2, between-group difference −0.35 ml/min
per 1.73 m2; 95 % confidence interval −2.9 to 2.3) [163].
There are also novel data in dialysis patients regarding
an innovative iron compound. Ferric pyrophosphate cit-
rate (FPC, Triferic™) is a carbohydrate-free, water-
soluble, complex iron salt that was first demonstrated to
deliver iron via dialysate in 1999, allowing maintenance
of hemoglobin (Hgb) concentration and iron balance
while reducing the need for IV iron by about 80 % [164].
Fishbane et al. showed data from two identical phase 3
RCT (CRUISE 1 and 2), conducted in 599 iron-replete
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chronic HD patients [165]. Patients were dialyzed with
dialysate containing 2 μM FPC-iron or standard dialys-
ate (placebo) for up to 48 weeks. Oral or intravenous
iron supplementation was prohibited, and doses of
erythropoiesis-stimulating agents were held constant.
Hemoglobin concentration was maintained constant in
the FPC group but decreased by 0.4 g/dL in the placebo
group (p <0.001, combined results; 95 % CI 0.2–0.6).
Placebo treatment resulted in significantly higher de-
creases from baseline in reticulocyte hemoglobin content
(−0.9 pg versus −0.4 pg, p <0.001) and serum ferritin
(−133.1 μg/L versus −69.7 μg/L, p <0.001) compared
with FPC treatment [165]. Additional data were pro-
vided by the PRIME study. This 9-month, randomized,
placebo-controlled, double blind, multicenter clinical
study included 103 patients undergoing HD. The FPC
group received dialysate containing 2 μmol/l of iron.
The placebo group received standard dialysate. Intraven-
ous iron was administered according to the approved in-
dication when ferritin levels fell below 200 μg/l. ESA use
was 35 % lower in dialysate iron group compared with
placebo. Interestingly, ESA use increased in both groups,
but much more in the placebo group. Fewer patients in
the dialysate iron group needed or received IV iron
(51 % less iv iron). Adverse and serious adverse events
were similar in both groups [166].
Dialysis
Mortality risk in hemodialysis patients remains elevated
and is mostly linked with cardiovascular complication
and infection [167, 168]. A better strategy to recognize
those patients with increase risk of death is desirable.
Recently, a new model was validated in the second Ana-
lyzing Data, Recognizing Excellence and Optimizing
Outcomes (AROii) cohort. This database of 11,508 en-
tries contains demographic and biochemical observa-
tions of incident hemodialysis patients (median dialysis
vintage, 4 months). This scoring model was validated ex-
ternally using similar-sized Dialysis Outcomes and Prac-
tice Patterns Survey (DOPPS) data [169]. For AROii, the
observed 1- and 2-year mortality rates were 13.0 (95 %
confidence interval (CI; 12.3–13.8) and 11.2 (10.4–12.1)/
100 patient years, respectively. The greatest predictor of
mortality was patient age, with the risk for mortality be-
ginning at age 60 and increasing thereafter. C-reactive
protein and albumin were the best biochemical parame-
ters that contributed to mortality. Additionally, low body
mass index, history of cardiovascular disease or cancer,
and use of a vascular access catheter during baseline
were consistent predictors of mortality [169].
The benefit of dialysis is undeniably extended survival
in patients with ESRD. However, elderly patients on dia-
lysis have a high incidence of chronic health conditions,
frailty, falls and cognitive impairment [170]. In this
context, life expectancy for many elderly ESRD patients
is similar or worse than that associated with common
cancers, and HD does not always substantially prolong
life among older adult [171]. A shared decision-making
tool could help elderly advanced CKD patients decide
about initiating dialysis. Recently, a predictive risk score
for early mortality after dialysis initiation in the elderly
was derived and validated. Using US Renal Data System
and claims data from the Centers for Medicare &
Medicaid Services for 69,441 (aged ≥67 years) patients
with end-stage renal disease who initiated dialysis ther-
apy from January 1, 2009, to December 31, 2010 a sim-
ple risk score was validated. This simple risk score (total
score, 0–9) included age (0–3 points), low albumin level,
assistance with daily living, nursing home residence, can-
cer, heart failure, and hospitalization (one point each);
The highest scores (above eight) indicated an estimated
39 and 55 % probability of death within the first 3 and
6 months, respectively [172]. For a patient with a score
of three, the estimated probability of death at 3 and
6 months were 12 and 20 %, respectively [172].
Hemodialysis is the most routinely used renal replace-
ment therapy for end stage renal disease (ESRD)
patients. Arterio-venous fistulae remain the most preva-
lent access for hemodialysis. The rates of thrombosis
and maturation failure are still high; at 1 year primary
patency rates vary between 50 and 80 % [173]. Fish oil
with its anti-proliferative, anti-oxidant, and vasodilator
effects, could theoretical be efficient for preventing de-
velopment of AV-graft stenosis and thrombosis [173].
However, in a randomized control trial, neither aspirin
or fish oil administration did not improve the FAV pa-
tency at 1 years in adult patients with CKD stage 4 or 5,
already on HD on where HD is planned to start within
6 months [174]. Four grams of fish oil or placebo were
given for 12 weeks to 567 patients and a subgroup of
patients were assigned to aspirin 100 mg or placebo.
There was an overall rate of 47 % AVF failure and
aspirin or fish oil did not change the outcomes [174].
Uremic pruritus affects almost 50 % of patients with
ESRD and often causes sleep disturbance, long term
pain and impaired quality of life [175]. Recent pre-
sented data showed that nalbuphine, an opioid agonist
reduces symptoms of uremic pruritus [176]. Three hun-
dred seventy-three hemodialysis patients were assigned
to take nalbuphine 120 mg (n = 120), nalbuphine 60 mg
(n = 128) or placebo (n = 125) for a period of 6 weeks
[177]. Primary outcome was the numerical rating scale
score (NRS) of worst itching intensity for each dose of
nalbuphine versus placebo. Patients receiving 120 mg
nalbuphine showed a significant reduction of itch in-
tensity by 49 %. A non-significant reduction was also
noted in the 60 mg group; a post-hoc analysis showed
that patients who received 120 mg and had at baseline
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a NRS score of seven or above had not only a signifi-
cant NRS reduction, but also an improvement in sleep
quality according to the ITCH Medical outcomes Study
sleep scale. Most adverse events were nausea and
vomiting; they were not different between dose treat-
ment groups and were attenuated after the second week
of treatment [177].
Conclusions
Year 2015 has been extremely important and interesting
in the field of lipid, blood pressure and kidney research.
IMPROVE-IT trial revalidated the concept “lower is bet-
ter” for LDL-C as a target for therapy, increasing the ne-
cessity of treatment the high-risk patients to achieve
LDL-C goals, and suggesting the benefits of new goal of
50 mg/dL and lower. For the statin-intolerant patients
and those requiring essential reductions in LDL-C to
achieve their goals, new therapies, including PCSK9 in-
hibitors remain promising drugs. In BP research, AHA/
ACC 2015 guidelines recommended a target for BP
below 140/90 mmHg in stable or unstable CAD patients
and below 150/90 mmHg in patients older than 80 years
of age, however the recent results of the SPRINT trial
have suggested that there might be significant benefits,
taking into account CV risk, for hypertensive patients
over 50 without diabetes and BP levels <120/80. Finally,
in kidney research, reducing the progression of CKD
and related complications such as anemia, metabolic
acidosis, bone and mineral diseases, AKI and CVD is
still a goal for clinicians.
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